As Genentech and NVIDIA enter into a multi-year strategic AI research collaboration to accelerate drug discovery and development, web editor Nicole Raleigh revisits a recent discussion with
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.